- Global Pharma News & Resources

Angiosarcomas Treatment Market 2019 Trends, Size Analysis, Share, Leading Companies, Future Insights and Top Manufacturers, Forecast To 2026

Angiosarcoma is rare cancer that mostly occurs in the inner lining of blood vessels of the body, including the skin, breast, liver, spleen, and deep tissue and is produced due to the transformation of mesenchymal cells.  Surgery, chemotherapy, and radiotherapy are the most typical form of the treatment available for angiosarcoma. Types of angiosarcoma are epithelioid angiosarcoma, cardiac angiosarcoma, hepatic angiosarcoma, and cutaneous angiosarcoma.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

As per the stats of Know Cancer—an institute is known for connecting cancer infected people to empower and educate them about cancer—cutaneous angiosarcoma contributes to the maximum of angiosarcoma cases, which is around 60% followed by angiosarcoma found in deep tissue and in breast tissue contributes around 35% of overall cases. Symptoms associated with angiosarcoma include skin lesions, bone pain, fatigue, anemia, and heart pain, though these vary according to the location of the angiosarcoma.

According to the National Cancer Institute (NCI), around 50% of the people suffering from angiosarcoma, have a survival rate of around 5 years from the onset. Those who respond to treatment and show some recovery in the first 5 years after diagnosis of angiosarcoma have higher chances of survival than those that are not diagnosed on time. According to the data published by NCI in 2014, based on a 5-year study, the survival rate for sarcoma was pegged at 90% at the first stage, 81% at the second stage, 56% during the third stage, while survival during the fourth stage is highly unlikely. Diagnostics tests such as CT, PET, MRI scan, and biopsy tests are widely used for the effective diagnosis of angiosarcoma.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @

As per the results of a study by Coherent Market Insights, in August 2015, the incidence rate for this disease is low, with angiosarcoma contributing to 1-2% towards sarcoma cases. A growing number of cancer cases inadvertently around the globe is expected to create a highly conducive environment for the growth of the angiosarcoma treatment market.

As per stats published by the European Medicines Agency in January 2017, around 3.5 in 10,000 people were affected by angiosarcoma in Europe, in 2016. While in the U.S., angiosarcoma accounted for only 0.7% of cancer cases, making it a rare type of cancer.

Market Taxonomy:

By Location of Instigation

  • Hemangiosarcoma
  • Lymphangiosarcoma

By Type of Treatment

  • Surgery
  • Chemotherapy
  • Radiotherapy

To understand Research Methodology, please click

Rising prevalence of angiosarcoma disease and increasing research and development to boost the market growth

The market in North America accounts for the largest share in the global market, as most of the major research and development activities are carried out in this region. Followed by Europe, which is backed up by rising healthcare infrastructure, availability of affordability of drugs, and rising awareness regarding available treatments in the region.

The high cost of the research and development activities as the disease is rare is expected to act as a major restraining factor for the growth of the angiosarcoma treatment market. Nevertheless, due to the increasing incidence of the disease, the market is expected to witness the entry of new players.

Major companies involved in the angiosarcoma treatment market include Genentech, Inc., Pfizer Inc., Janssen Global Services, LLC, Bayer AG, Sanofi, and Amgen Inc.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 02-Mar-2021